<DOC>
	<DOCNO>NCT02864004</DOCNO>
	<brief_summary>The aim study ass use apomorphine pump earlier stage Parkinson ' Disease ( PD ) , motor complication develop patient significantly affect social occupational functioning . The investigator hypothesize apomorphine pump superior term positive impact quality life ( QoL ) oral medical therapy alone relatively early stage PD , appearance severe disable motor complication thus favor maintain patient ' social occupational status significant positive economic impact health system .</brief_summary>
	<brief_title>Apomorphine Pump Early Stage Parkinson 's Disease ( EARLY-PUMP )</brief_title>
	<detailed_description>The recruitment period 24 month . The duration study period one year patient due : - adjustment apomorphine pump parameter oral medication ( 3 month interval ) , - motor psychosocial change need time develop impact QoL . At end study period , two additional visit Months 18 24 perform long term follow collect QoL cost related data require medico-economic analysis . APOMORPHINE ( APO ) group : The apomorphine pump instal adjusted baseline first hospitalization ( 10 day ) . Modifications hourly flow pump readjustment ( reduction ) anti-parkinsonian oral medication check performed Months 1 , 2 , 4 , 5 , 6 , 9 visit phone call , month 3 3 day hospitalization . Clinical evaluation perform month 6 12 . Control group : Patients treat optimized medical treatment accord guideline European Federation Neurological Societies . Dose adjustment do Months 3 , 6 , 9 . Clinical evaluation perform month 6 12 . In group , data medico-economic evaluation collect patient baseline , Months 6 , 12 , 18 24 Quality Adjusted Life Year ( QALYs ) cost relate data patient 's diary French Health Insurance database .</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Apomorphine</mesh_term>
	<criteria>Adults age ≤ 65 year , Idiopathic PD ( According British Brain Bank Criteria ) without know suspected cause Parkinsonism , Hoehn Yahr stage ≤ 2.5 best ON , Disease duration ≥ 4 year , Presence fluctuation and/or dyskinesias 3 year , One two follow form impairment : Impairment activity daily live ( MDSUPDRS II &gt; 6 ) due PDsymptoms despite medical treatment bad condition , Impairment social occupational functioning ( measure SOFAS ) due PDsymptoms despite medical treatment ( 5180 % ) , PDQ39 complete , Able understand remember component study , Written inform consent , Patients cover social insurance . Dementia ( MoCA &lt; 22 ) , Major uncontrolled depression time assessment ( BDI &gt; 25 ) Bipolar disease , Active hallucination history hallucination past year , Need nursing care , Previous use apomorphine pump treatment , History respiratory depression , History deep brain stimulation lesional surgery PD intrajejunal LDopa , Presence severe freeze clinically relevant postural instability lead fall ON state , Symptomatic clinically relevant medically uncontrolled orthostatic hypotension , Clinically relevant hepatic dysfunction ( total bilirubin &gt; 2.0 mg/dL , Alanine Amino Transferase ( ALT ) Aspartate Amino Transferase ( AST ) &gt; 2 time upper limit normal ) , Clinically relevant renal dysfunction ( serum creatinine &gt; 2.0 mg/dL ) , Pregnant breastfeed woman , Hypersensitivity apomorphine excipients medicinal product , Concomitant therapy within 28 day prior baseline : alphamethyl dopa , metoclopramide , reserpine , neuroleptic ( except Clozapine ) , methylphenidate , amphetamine , intrajejunal Ldopa , History current drug alcohol abuse dependency , Patients borderline QT interval correct heart rate accord Bazett 's formula ( QTc ) &gt; 450 m male &gt; 470 ms female screen history long QT syndrome ; &gt; 450 m absolute duration , Adults legally protect ( judicial protection , guardianship supervision ) , person deprive liberty .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Parkinson disease</keyword>
	<keyword>Quality Life</keyword>
	<keyword>Apomorphine infusion</keyword>
</DOC>